LiverMultiScan
General Information
Product name
Company
Subspeciality
Modality
Disease targeted
Not specified
Main task
Not specified
Technical Specifications
Population
Not specified
Patient population age
Not specified
Input
Not specified
Input format
Not specified
Output
Not specified
Output format
Not specified
Integration
Not specified
Deployment
Not specified
Trigger for analysis
Not specified
Processing time
Not specified
Regulatory Information
Pathway:
MDR
Class:
Class IIb
Pathway:
510(k) cleared
Class:
Class II
Other certifications
Not specified
Market Presence
On market since
AI Platforms
Resellers
Not specified
Countries present
Not specified
Paying clinical customers
Not specified
Research/test users
Not specified
Pricing Information
Pricing model
Not specified
Based on
Not specified
Evidence & Research
Peer-Reviewed Papers
View
Utility and cost-effectiveness of LiverMultiScan for MASLD diagnosis: a real-world multi-national randomised clinical trial
View
LiverMultiScan as an alternative to liver biopsy to monitor autoimmune hepatitis in the National Health Service in England: an economic evaluation
Source: public | First published: Feb 19, 2024 | Last updated: Jul 9, 2025